News
Featured News
The Potential of Von Willebrand Factor to Safely Target Large Vessel Occlusion While also Preventing Downstream Hemorrhages
February 25, 2025
Basking co-founder and CMO Shahid Nimjee, M.D., and interventional cardiologist C. Michael Gibson, M.S., M.D. discuss Basking’s revolutionary approach to treat acute ischemic stroke.
Read More
Press Releases
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
September 11, 2024
Novel RNA aptamer designed to inhibit the function of von Willebrand Factor and promote thrombolysis Columbus, Ohio – Sept. 10,...
Read More
Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke
February 1, 2024
Financing will fund upcoming Phase 2 trial of BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF) in development...
Read More
Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference
May 9, 2023
-Phase 2-Ready Drug Candidate Offers Potential to Greatly Broaden the Acute Ischemic Stroke Population Who Can Benefit from Thrombolytic Therapy-...
Read More
Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023
February 9, 2023
-BB-031, a potential rapid onset, short-acting and reversible thrombolytic, targets von Willebrand Factor, a key structural component of thrombi and...
Read More
Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023
January 31, 2023
Columbus, OH: January 31, 2023: Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke,...
Read More
